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Hepatitis C virus-associated giomerulonephritis. Effect of a-interferon
therapy. Hepatitis C virus (HCV) infection may present as a primary
glomerular disease. We report 34 adult patients who presented with
proteinuria and had circulating anti-HCV antibodies. Primary risk factors
included a history of intravenous drug abuse (56%) or blood transfusion
(18%). Patients presented with nephrotic syndrome (71%) or with non-
nephrotic proteinuria (29%) and had membranoproliferative or acute
proliferative glomerulonephritis on renal biopsy. Signs of clinical liver
disease were infrequent (18%), though elevated liver function tests were
common (66%) and liver biopsy in 16 of 18 patients showed chronic active
hepatitis. Cryoglobulinemia was frequent (59%), but only 44% had
extrarenal manifestations. In 100% of cases tested, HCV RNA could be
found in the serum or cryoprecipitates. Fourteen patients received inter-
feron alpha for 6 to 12 months with a significant reduction in proteinuria
but no improvement in renal function. A good clinical response correlated
with disappearance of HCV RNA from the serum during treatment;
however, relapse of viremia and renal disease was common after complet-
ing therapy. Evidence for HCV infection should be sought in all patients
with primary glomerular disease. The optimal treatment strategy, how-
ever, remains to be defined.
It is now established that hepatitis C virus (HCV) infection is a
major cause of mixed cryoglobulinemia [1—6]. Less well known,
however, is that HCV infection may cause membranoprolifera-
tive, proliferative, or membranous glomerulonephritis [7—12].
Although ciyoglobulinemia is commonly present in patients with
HCV-associated glomerulonephritis, many have no extrarenal
manifestations of cryoglobulinemia and liver function tests may be
normal [7—12]. As such, the clinical presentation often suggests a
primaly renal disease.
We report the clinical and virologic manifestations of 34
patients with HCV-associated glomerulonephritis, with special
emphasis on their response to recombinant interferon alpha
(IFN-a) therapy.
Methods
Consultation was provided on forty adult patients with protein-
uria and a positive antibody test for HCV infection who under-
went a renal biopsy by practicing nephrologists. All but one of
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these patients were negative for the hepatitis B surface antigen
(HBsAg). The patient who had circulating HBsAg at the time of
presentation tested negative for both HBV DNA and HCV RNA
by reverse transcriptase polymerase chain reaction (RT-PCR).
This patient, who had MPGN type III, had a 50% reduction in
proteinuria following his spontaneous loss of HBsAg and the
appearance of anti-HBs antibodies in his serum, and was there-
fore considered to have a HBV associated MPGN and was
excluded from the study. Five patients had membranous nephrop-
athy on renal biopsy and will be the subject of a separate report.
Of the remaining 34 patients, 20 were from the state of Washing-
ton, whereas the rest were referred from elsewhere in the United
States. The initial presentation of five of these patients has been
previously reported [7].
Verification of HCV infection was obtained in all patients by
testing for the presence of HCV antibodies using the second
generation enzyme immunoassay (Abbott Laboratories, North
Chicago, Illinois, USA) or by recombinant immunoblot assay
(Ortho Diagnostics, Raritan, New Jersey, USA). In all cases in
which serum and cryoprecipitates were available, the presence of
HCV RNA was sought by RT-PCR using primers derived from
the 5'-noncoding, highly conserved region of the HCV genome as
previously described [7]. HCV genotyping was performed by PCR
using primers specific for the HCV core region [13] and confirmed
by sequence analysis of the NS5 region [14].
After giving informed consent, 19 patients were treated with
recombinant IFN-a (Intron-A, Schering-Plough, Bloomfield, New
Jersey). Treatment was administered as 3 million U subcutane-
ously three times per week for 6 to 12 months, with dosage
adjustments made depending on tolerance of the treatment.
Results
Thirty-four patients were identified with proteinuria and circu-
lating anti-HCV antibodies. The mean age was 46 years (range 36
to 80); 59% were male; the majority (74%) were white, although
some were black (9%), Hispanic (6%), Filipino (6%), and Asian
(6%). Risk factors for HCV infection were present in 79% of
patients; these included a history of intravenous drug abuse (56%)
which was often remote, and prior blood transfusion (18%). Two
patients (6%) gave a history of sexual exposure to HCV (both had
partners that were intravenous drug addicts, and one of the
addicts had a history of nonA-nonB hepatitis).
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Table 1. Clinical presentation of patients with HCV infection and glomerulonephritis
EMC, Cryo+(N = 11)
GN, Cryo+(N = 9)
GN, Cryo-(N = 10)
EMC, Ciyo-(N = 4)
Total
34
Ageyeai 48±14 46±9 45±6 44±5 46±8
Sex (M/F) 5/6 6/3 5/5 4/0 20/14
HCV RNA+ (PCR) 10/10 8/8 7/7 3/3 28/28
HCV genotype 1(3), 11(3), III (1), IV (3) 1(3), 11(1), HI (1), IV (3) 1(2), 11(5) 1(1), 11(2), IV (1) 1(9), 11(11), 111(2), IV (7)














MPGNI ioa 7 7 4 28
MPGNIII 0 1 2 0 3
ProlifGN 1 1 1 0 3
AST/ALT 7/11 (64%) 5/9 (56%) 8/10 (80%) 3/4 (75%) 23/34 (68%)
Clinical liver
diseas&'
1/11 (9%) 2/9 (22%) 3/10 (30%) 0/4 (0%) 6/34 (18%)
J, CH5O 7/8 (88%) 6/6 (100%) 3/4 (75%) 3/3 (100%) 19/21 (90%)
J. C3 5/11 (45%) 4/9 (44%) 4/7(54%) 2/4 (50%) 15/31 (48%)
, C4 10/11 (91%) 6/9 (66%) 4/8 (50%) 2/4 (50%) 22/32 (69%)
+RF 8/9 (89%) 5/8 (62%) 4/8 (50%) 4/4 (100%) 21/29 (72%)
Developed EMC and — 0 2 4 6
Ciyo later
Developed Cryo — — 3 — 3
later
a-IFN therapy (JV)C 4 4 3 3 14
Improved 3 3 3 2 11
No response 1 1 0 1 3
Patients presented with proteinuria and positive HCV antibody were categorized as to the presence of extrarenal signs of mixed cryoglobulinemia
(EMC) or whether they appeared to have primary glomerular disease (GN), and whether or not cryoglobulinemia (Cryo) was detected. Four patients
did have a history of a purpuric rash, but were initially negative for cryoglobulinemia at the time of renal biopsy (EMC, Cryo—). These latter patients,
however, developed clyoglobulinemia over the ensuing months.
Abbreviations are: ALT, alanine aminotransferase; AST, aspartate aminotransferase; RF, rheumatoid factor.
a 2 cases also showed a small to medium vessel arteritisbSigns of liver disease (ascites, hepatomegaly, or telangiectasia)
C Treated for 6 months or longer
Clinical presentation
All patients were referred to nephrologists for the evaluation of
proteinuria and microhematuria. However, the clinical presenta-
tion differed among the patients (Table 1). In 11 patients extra-
renal signs of cryoglobulinemia (for example, purpura, arthralgias,
cardiomyopathy, etc.) were present in association with circulating
cryoglobulins, consistent with a diagnosis of "essential" mixed
cryoglobulinemia (EMC). Nineteen patients appeared to have a
primary glomerular disease; however, nine of these patients had
circulating cryoglobulins. Four patients gave a history of a pur-
puric rash in addition to the renal disease suggestive of EMC, but
initially tested negative for cryoglobulinemia.
Despite the differences in clinical presentation, virologic and
laboratory analyses were remarkably similar between groups
(Table 1). In addition, patients could switch categories over time.
Five patients who initially presented with a noncryoglobulinemic
glomerular disease subsequently developed detectable cryoglob-
ulinemia, and in two of these cases this was associated with the
development of purpura (Table 1). In addition, all four patients
with a history of purpuric rash and noncryoglobulinemic MPGN
eventually tested positive for cryoglobulinemia (Table 1). Given
these considerations, the clinical features of the group of patients
as a whole will be considered in the subsequent sections. However,
specific analysis of the clinical features of each group can be found
in Table 1.
Renal manifestations
Patients presented with nephrotic (that is, > 3.5 g'day; 71%) or
non-nephrotic (29%) proteinuria (24 hr urine protein excretion of
5.9 5.2 g/day, range 0.5 to 28) with modest azotemia (serum
creatinine 1.8 0.9 mg/dl, range 1.0 to 5.6). Hypoalbuminemia
(3.0 g/dl or lower) was present in the majority (72%) of patients
(mean concentration 2.8 0.5 g/dl). Renal biopsy demonstrated
a membranoproliferative glomerulonephritis (MPGN) type I in 28
cases (82%). In three cases (9%) MPGN type III was diagnosed,
as defined as an MPGN-type lesion in which immune deposits
were found in subepithelial areas in addition to the subendothe-
hum and mesangium. In three cases (9%) an acute proliferative
and exudative nephritis was diagnosed, and in two cases an
arteritis involving small and medium renal arterial vessels was also
present. Immunofluorescence demonstrated capillary wall depo-
sition of 1gM (88%), IgG (65%), and C3 (82%) in the majority of
cases, but deposition was often scant. Electron microscopy in 29
cases revealed subendothelial dense deposits in 93% of cases,
occasionally (14%) with coexistent subepithelial and intramem-
branous deposits.
Hepatic manifestations
Clinical signs of liver disease (that is, spider telangiectasias,
hepatomegaly or ascites) were infrequent (18%); however, liver
enzymes (alanine and/or aspartate aminotransferase levels) were
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mildly elevated in two-thirds of these patients. Despite the
minimal evidence for liver disease, liver biopsy in 18 patients
revealed chronic active hepatitis (N = 16), often with cirrhosis (N
= 9); in two cases chronic persistent hepatitis was present.
Presence of cyog1obulinemia and other laboratory findings
Cryoglobulinemia was present in 59% of patients at presenta-
tion; however, an additional 26% developed cryoglobulinemia
during the subsequent months. In seven cases the cryoglobulins
were typed and shown to be type II, usually with an IgMK (N =6);
although an IgMA (N 1) was also observed. Despite the
presence of cryoglobulinemia, extrarenal manifestations of cryo-
globulinemia were absent in the majority (56%) of patients at
presentation, although eventually 50% did have some extrarenal
signs (Table 1). The extrarenal manifestations consisted of pur-
pura (35%), arthralgias (12%), neuropathy (9%), abdominal pain
(6%), and cardiomyopathy (6%). One patient also had a non-
Hodgkins lymphoma.
Other laboratory findings included depressed total plasma
hemolytic complement (CH5O) (90% of cases tested), and low C3
(48%) and C4 (69%) levels. Rheumatoid factor activity was
present in 72%, and antinuclear antibodies were either absent
(88%) or present in low titer (12%). Anti-neutrophil cytoplasmic
antibodies were negative in the 17 cases tested.
Virologic studies
All 34 patients had evidence for HCV infection based on the
presence of anti-HCV antibodies. Evidence for prior hepatitis B
virus (HBV) infection was present in 14 of 31 cases tested (that is,
anti-HB core Ag or anti-HBs antibodies). In addition, HCV RNA
was detected (by PCR) in the serum of 28 of 28 cases tested
(100%), and in the cryoglobulins of 22 of 23 cases (96%). In one
patient HCV RNA was detected in only one of three blood
samples. HCV genotyping was performed on the sera of 26
patients. Genotype analysis was performed on 29 isolates (due to
3 patients with dual infections), and were classified as type I (N =
9), type II (N = 11), type III (N = 2), and type IV (N = 7) (types
la, ib, 2a, and 2b, respectively, according to Simmonds et al [14]).
Effect of treatment with recombinant interferon alpha
IFN-a has been administered to 19 patients; in two cases it was
discontinued due to either worsening neuropathy or the develop-
ment of erythema multiforme. In another case IFN-a was admin-
istered to a patient with a creatinine of 5.2 mg/dl and a urinary
protein excretion of 28 glday. This patient's renal disease pro-
gressed rapidly and the a-IFN was discontinued at one month
when dialysis became necessary.
Fourteen of the 16 remaining patients have received six or more
months of IFN-a. In these patients, urine protein excretion was
reduced (pretreatment 5.8 4.1 g/day vs. post-treatment 2.0 2.6
g/day, P < 0.005 by paired Student's t-test). In seven cases protein
excretion decreased to less than 1 g/day, In 11 of 14 cases, serum
creatinine improved 0.2 mg/dl or greater. However, no significant
improvement in serum creatinine was observed when all of the
patients were analyzed as a group (pretreatment 2.0 0.7 mg/dl
vs. posttreatment 1.5 0.6 mg/dl, P = NS).
In 11 cases sera was tested for HCV RNA while on therapy.
The six patients that became negative for HCV RNA during
therapy had a relatively better clinical response to IFN-a than the
five patients who remained HCV RNA positive (Table 2). Reso-
HCV RNA negative HCV RNA + during
during a-IFN (N = 6) a-IFN (N = 5)
Before After Before After
Creatinine mg/dl
Urine protein g/day
aP < 0.02 by paired t-test
1.8 0.5 1.5 0.7 2.0 0.8 1.8 0.8
6.1 4.6 1.3 1.5 6.1 3.3 4.2 4.2
lution of HCV viremia was also associated with normalization of
liver function tests in all five patients in which they were abnor-
mal.
The relationship between the clinical response to IFN-a and
the HCV genotype was examined. A complete remission of the
proteinuria (that is, <500 mg/day) was observed in four patients
(1 type I and 3 type II); a partial remission (protein excretion
<2 gms/d) was seen in six patients (1 type 1, 1 type II, 1 type IV,
1 with dual infection with types I and IV, and 2 that were not
typed); and proteinuria greater than 2 g/day persisted in four (3
patients with type I, and 1 patient that was not typed). In addition,
three of the five patients that remained HCV RNA positive during
therapy had the type I HCV genotype.
Five of the six patients that became negative for HCV RNA in
their serum have discontinued the IFN-a. In all cases, viremia has
recurred within three months of completing therapy. This was
followed by a rise in liver function tests (3 cases, at 4 to 5 months),
a recurrence of the nephrotic syndrome (3 cases between 2 and 18
months), and recurrent purpura (1 case at 3 months). IFN-a
therapy has been re-initiated in three of these patients. In three
patients who have remained HCV RNA positive on standard
doses of c-IFN, the dose has been increased to 5 to 6 million U
three times weekly. Although the data are preliminary, one of
these patients appears to be responding (serum creatinine has
decreased from 3.4 mg/dl to 1.6 mg/dl with a decrease in protein
excretion from 14 g/day to 2.3 g/day).
Side effects of IFN-a included a flu-like syndrome observed in
the majority of patients and which gradually improved during
therapy. Occasional patients complained of fatigue, irritability,
depression, or headache. Two patients developed erythema mul-
tiforme. Three patients were also given erythropoietin (50 units
per kg of body weight per week) because of anemia.
Immunosuppressive treatment has also been administered to
patients with HCV-associated nephritis. No effect on renal func-
tion was observed in five patients treated with oral prednisone,
although it may have improved the purpura seen in two patients.
One patient with EMC and MPGN was being tapered off of
prednisone during a-IFN therapy and had a flare of his renal
disease when his prednisone dose was reduced from 5 to 2.5
mg/day, with a sudden increase in his creatinine (from 1.3 to 2.8
mg/dl) and protein excretion. This patient, who had continued to
be HCV RNA positive on a-IFN therapy, was then administered
a short course of high dose oral steroids which was associated with
an improvement in his creatinine to 1.7 mg/dl. Pulse steroids (1 g
i.v. daily for 3 days followed by a tapering oral prednisone course)
were given to two patients, including to one patient who had
become dialysis dependent over several weeks prior to this
therapy. One of these patients had EMC with cryoglobulinemic
MPGN whereas the other patient had noncryoglobulinemic
Table 2. Clinical response of renal disease to IFN-a therapy as it
relates to the suppression of viremia during therapy
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MPGN. In both cases an improvement in renal function was
observed, and in the one patient dialysis has been discontinued
and the creatinine is now 2.4 mg/dl. However, both patients
remain HCV RNA positive. Cytotoxic agents and corticosteroids,
with/without plasma exchange, have also been administered to five
patients. Three of these patients (including two patients that were
77 and 80 years old) died of sepsis, pneumonia, and/or adult
respiratoly distress syndrome. One patient who received chemo-
therapy for his lymphoma, and one patient who received a liver
transplant, have had improvement in their renal function, but
have had either an exacerbation or recurrence of their hepatitis
and have remained HCV RNA positive.
Discussion
Our studies (7, and the current report) and that of others [5,
8—12] have demonstrated that HCV infection may be associated
with renal disease. Whereas the association of HCV infection with
"essential" mixed cryoglobulinemia is well-known [1—6], it is also
apparent that HCV infection may manifest as a primary glomer-
ulonephritis without clinical evidence for liver disease or cryoglob-
ulinemia [7, and this series]. In this series 19 of 34 patients (56%)
presented as a primary glomerular disease, and 10 of these
patients (29%) lacked detectable cryoglobulins (Table 1). Biopsy
findings usually showed "idiopathic" MPGN type I, and occasion-
ally MPGN type III, membranous nephropathy, or acute prolif-
erative GN [7—12, and this series]. A recent study in Japan
suggests that HCV infection may account for 60 percent of cases
of adult MPGN [10]. This suggests that all patients presenting
with glomerulonephritis should be screened for HCV infection.
The clinical characteristics of the patients with EMC and
cryoglobulinemic MPGN were remarkably similar to those pa-
tients who presented as either cryoglobulinemic or noncryoglobu-
linemic MPGN and no extrarenal symptoms (Table 1). Further-
more, patients who initially tested negative for cryoglobulins could
develop cryoglobulinemia with or without extrarenal manifesta-
tions. This suggests that these disease entities may actually
represent one continuous spectrum, with EMC on one end and
MPGN on the other.
This also raises the question of whether or not idiopathic
MPGN type I should be considered a distinct entity. Studies
performed in the early 1970s demonstrated a significant occur-
rence of cryoglobulinemia in three "primary" glomerular diseases;
specifically, MPGN, acute proliferative GN, and lupus nephritis
[15]. Thirty-two percent of patients with MPGN were found to
have cryoglobulinemia [15]. It seems likely that many of these
patients had HCV infection.
In this study, patients were referred to nephrologists for
evaluation of HCV infection and proteinuria. Most patients
(71%) presented with nephrotic syndrome, and hypoalbuminemia
was often severe. Clinical evidence of liver disease (that is, ascites
or hepatomegaly) was observed in only 18% of patients, although
mildly elevated liver enzymes were frequently present, and when
liver tissue was examined chronic active hepatitis was diagnosed in
89% of cases. In the great majority of sera and cryoprecipitates
tested, HCV RNA was isolated. Genotyping showed that the
majority of cases were HCV type I or type II, which are the more
common genotypes present in United States (J. Lau, personal
communication).
Fourteen patients were treated with IFN-a for at least six
months. A significant reduction in proteinuria was observed,
whereas renal function improved but the improvement did not
reach statistical significance. Interestingly, not all patients treated
with IFN-a had a beneficial response, and this correlated with
whether or not HCV RNA remained detectable in the serum or
cryoprecipitates. Indeed, the three patients who did not appear to
respond at all to IFN-a remained HCV RNA positive and carried
the type I genotype. This genotype has been reported to be
relatively more resistant to IFN-a therapy [16].
Recently, Misiani et al reported a controlled study examining
the effect of IFN-a on the mixed cryoglobulinemia associated with
HCV [17]. These authors noted a significant reduction in purpura
and circulating cryoglobulins in those patients who became HCV
RNA negative during therapy [17]. One significant difference
between their study and ours was that patients were entered into
their series if they had symptoms of EMC (that is, fatigue,
arthralgias and purpura) and evidence for HCV infection,
whereas our patients were referred to nephrologists for evaluation
of glomerular disease. Although renal involvement, as manifested
by proteinuria and hematuria, was observed in two-thirds of their
patients, the renal disease was mild, as the mean creatinine was
1.2 mg/dl, the protein-creatinine ratio was 0.24 (equivalent to less
than 1 gram per day), and no renal biopsy findings were provided.
In contrast, 71% of our patients had nephrotic range proteinuria,
72% had serum albumin levels less than or equal to 3 g/dl, 68%
had a creatinine of 1.4 mg/dl or greater (with 2 eventually
requiring dialysis), and all underwent renal biopsy. Although the
pathogenic processes are likely similar in these studies, the
current series does provide the first detailed information on the
spectrum of HCV associated glomerular disease and its respon-
siveness to IFN-a. In that regard, proteinuria was significantly
reduced with therapy, and, like the Misiani study [17], the
beneficial effects of IFN-a were most impressive in those patients
in which the HCV RNA was suppressed during therapy. Unfor-
tunately, relapse of viremia and renal disease were common after
therapy was discontinued.
The optimal treatment strategy for patients with HCV-associ-
ated GN has yet to be established. It is possible that higher doses
or longer duration of therapy with IFN-a may be required. It is
also possible that combination therapies using interferon-a with
other antiviral drugs such as ribavirin may be more effective [18].
An alternative to IFN-a is immunosuppressive therapy, which
may work in these patients by suppressing the antibody response
as opposed to eliminating the antigen (that is, virus). In our
limited number of patients oral prednisone was without clinically
apparent effect on the renal disease, whereas cytotoxic therapy
appeared to be associated with severe untoward side effects. Pulse
steroid therapy was associated with improvement in the renal
function in the two patients who received this therapy, and is
consistent with studies by others using pulse steroid therapy in
cryoglobulinemic GN [19]. However, one problem with immuno-
suppressive therapies is that circulating HCV RNA levels increase
[20], and the consequence of the increased HCV viremia on the
underlying liver disease remains to be determined. Ultimately,
controlled trials comparing these types of therapy are indicated.
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